All In Biotech

NDA 212608 · Blueprint Medicines

Ayvakit

Avapritinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 9, 2020

Approved uses

5

Original approval plus efficacy supplements

Registered trials

21

1 Phase 3, 10 recruiting

FAERS reports

12,650

3,692 serious, 380 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 20, 2026.

AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.3 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM)...

Mechanism: Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants as well as multiple KIT exon 11, 11/17 and 17 mutants with half maximal inhibitory concentrations (IC 50s ) less than 25 nM in biochemical assays. Certain mutations in PDGFRA and KIT can result in the autophosphorylation and constitutive activation of these receptors which can contribute to tumor and mast cell proliferation. Other potential targets for avapritinib include wild type KIT, PDGFRB, and CSFR1. In cellular assays, avapritinib inhibited the autophosphorylation of KIT D816V with an IC 50...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 16, 2026 Supplement 21 · Efficacy OrphanLabelLetter
  • May 22, 2023 Supplement 13 · Efficacy · priority review OrphanLabelLetterReview
  • Jun 16, 2021 Supplement 6 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Jun 16, 2021 Supplement 7 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Jan 9, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
5 products under this application
  • AYVAKIT · AVAPRITINIB 50MG · TABLET, ORAL · Prescription
  • AYVAKIT · AVAPRITINIB 300MG · TABLET, ORAL · Prescription
  • AYVAKIT · AVAPRITINIB 100MG · TABLET, ORAL · Prescription
  • AYVAKIT · AVAPRITINIB 25MG · TABLET, ORAL · Prescription
  • AYVAKIT · AVAPRITINIB 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avapritinib" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,855
  • off label use1,451
  • nausea1,306
  • diarrhoea1,062
  • headache607
  • dizziness571
  • vomiting549
  • swelling face542
  • memory impairment532
  • asthenia497
  • product dose omission issue488
  • rash486

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20182
2020498
20211,383
20222,358
20231,775
20242,320
20252,496
20261,818

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ayvakit (Avapritinib)

2024 spending

$160M

Beneficiaries

547

4,023 claims

Per beneficiary

$292,553

$1,278.78 per unit

View as table
YearSpending
2020$6,909,824
2021$15,536,747
2022$32,282,509
2023$55,171,737
2024$160,026,588

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Blueprint Medicines

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.